

19 June 2019

## Collaboration Agreement – Further Information

---

Further to the announcement made by the Company in relation to the agreement with Little Green Pharma Ltd, the ASX has requested the following additional information.

The term sheet represents the proposed indicative basis upon which the parties propose to negotiate a fully termed funding and option agreement. The parties do not intend to be legally bound until they have entered a fully termed agreement including financial contributions that are acceptable to both parties.

As mentioned, OBJ and Little Green Pharma will contribute equally to the Curtin Research and Development services with the adaptation of the transdermal technology to deliver cannabinoid therapy transdermally, with a view to the joint ownership and commercialisation of the technology.

## ABOUT OBJ

---

OBJ develops proprietary magnetic microarray drug delivery and product enhancement technologies for the pharmaceutical, healthcare and consumer goods sectors. OBJ partners with other companies in the design and development of next generation products using physical science rather than chemistry to provide new levels of product performance without the cost of reformulation or new ingredient approvals.

OBJ offers a portfolio of proprietary technologies and supports its partners by providing IP-protected market exclusivity, expertise in magnetic array design, feasibility and efficacy and claims testing, engineering and production.

## ABOUT OBJ'S TECHNOLOGIES

---

OBJ has developed a number of physical enhancement technologies based on the interactions between ingredient molecules and weak atomic forces. These influence the movement and penetration through the skin of drugs, active ingredients and formulations at the molecular level.

Complex 3-D magnetic fields produced by low cost microarrays or powered electromagnetic inductors have the ability to repulse certain molecules to enhance diffusion and to alter the permeability of biological and non-biological targets.

OBJ's low cost microarray film technology that utilises diamagnetic repulsion, induced permeation and energy redirection has already reached international markets to provide OBJ's Partners with a new way of managing the speed, depth of penetration and delivery of active ingredients in a wide range of pharmaceutical, healthcare and consumer products.

### Directors

Mr Antonio Varano  
Mr Steven Schapera  
Mr Jeffrey Edwards  
Mr Cameron Reynolds  
Dr Chris Quirk

### Company Secretary

Mr John Palermo

### Registered Office:

284 Oxford Street  
Leederville  
Western Australia 6007  
Tel: +61 8 9443 3011  
www.obj.com.au  
ABN: 72 056 482 636

19 June 2019

## FORWARD-LOOKING STATEMENTS

---

This announcement contains certain “forward-looking statements” concerning OBJ. Where OBJ expresses or implies an expectation or belief as to future events or results, such expectation or belief is expressed in good faith and believed to have a reasonable basis.

Forward-looking statements provided in this announcement are based on assumptions and contingencies which are subject to change without notice. Such forward-looking statements including statements regarding intentions, planned events and potential results are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance.

There can be no assurance that actual outcomes will not differ materially from these forward-looking statements, and there are risks associated with OBJ and the industry which may affect the accuracy of the forward-looking statements. OBJ does not undertake any obligation to release publicly any revisions to any forward-looking statement to reflect events or circumstances after the date of this announcement or to reflect the occurrence of unanticipated events, except as may be required under applicable securities laws.

**For more information:**

Matthew Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

**Phone:** +61 451 896 420

**Directors**

Mr Antonio Varano  
Mr Steven Schapera  
Mr Jeffrey Edwards  
Mr Cameron Reynolds  
Dr Chris Quirk

**Company Secretary**

Mr John Palermo

**Registered Office:**

**284 Oxford Street  
Leederville  
Western Australia 6007**  
Tel: +61 8 9443 3011  
[www.obj.com.au](http://www.obj.com.au)  
ABN: 72 056 482 636